reports
Scandi Standard AB: 2 directors
Two Directors at Scandi Standard AB bought 152,534 shares at between 72.100SEK and 72.560SEK. The significance rating of the trade was 89/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ove...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Capital Increase in Genmab as a Result of Employee Warrant Exercise Company Announcement COPENHAGEN, Denmark; May 7, 2024 – (Nasdaq: GMAB) will increase its share capital by 6,959 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 2,171 shares at DKK 1,025.00,2,790 shares at DKK 1,032.00,98 shares at DKK 1,161.00,729 shares at DKK 1,334.50,343 shares at DKK 1,362....
Transactions in Connection with Share Buy-back Program
Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; May 6, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. The share buy-back program is expected to be completed no later than December 16, 2024. The following transactions were executed under the program from April 29, 2024 to May 3, 2024: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)Accumulated through last announcement 602,818 1,222,541,085.50April 29, 202...
- ABGSC Food & Beverage Research
- Martin Kaland
- Simon Brun
- Rune Majlund Dahl
Genmab (Buy, TP: DKK2630.00) - Epinkly off to a good start in 2024
Q1 sales beat our forecast and consensus due to higher product-related royalties and solid Epkinly sales, while the operating profit margin was softer than expected owing to higher opex. Genmab reiterated the 2024 guidance for sales of DKK18.7bn–20.5bn, opex of DKK12.4bn–13.4bn, and operating profit of DKK4.6bn–7.1bn. We expect a strong pipeline of news flow in 2024. We reiterate our BUY and DKK2,630 target price.
Genmab Announces Financial Results for the First Quarter of 2024
Genmab Announces Financial Results for the First Quarter of 2024 May 2, 2024 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2024 Highlights The U.S. Food and Drug Administration (U.S. FDA) granted Priority Review for the supplemental Biologics License Application (sBLA) for EPKINLY® (epcoritamab-bysp) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy, with a Prescription Drug User Fee Act (PDUFA) target action date of June 28, 2024An additional Phase 3 clinical trial was initiated...
- Hanna Lindbo
Nobia (Hold, TP: SEK5.00) - Ongoing renovation
We have lowered our 2024–2025e sales slightly and our adj. EBIT by 10–5% ahead of the Q1 results. While we find Nobia’s financial position has improved significantly following the de-leveraging measures, we see some demand uncertainty into 2025 and 2026 (primarily in the Project business), and reiterate our HOLD, but have raised our target price to SEK5 (3.58), based on a blended 2-year forward EV/sales of 0.65x.
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat R...
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer Company Announcement Full approval based on global Phase 3 study demonstrating overall survival benefit of TIVDAK compared to chemotherapyTIVDAK is the first antibody-drug conjugate in this patient population to have positive overall survival data COPENHAGEN, Denmark; April 30, 2024 – (Nasdaq: GMAB) and (NYSE: PFE) announced today the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for TIVDAK® (tisotumab vedotin-tftv) f...
Transactions in Connection with Share Buy-back Program Genmab
Transactions in Connection with Share Buy-back Program Genmab Company Announcement COPENHAGEN, Denmark; April 29, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. The share buy-back program is expected to be completed no later than December 16, 2024. The following transactions were executed under the program from April 22, 2024 to April 26, 2024: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)Accumulated through last announcement 408,701 836,159,5...
Transactions in Connection with Share Buy-back Program Genmab
Transactions in Connection with Share Buy-back Program Genmab Company Announcement COPENHAGEN, Denmark; April 22, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. The share buy-back program is expected to be completed no later than December 16, 2024. The following transactions were executed under the program from April 15, 2024 to April 19, 2024: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)Accumulated through last announcement 269,334 555,043,478.37Ap...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarte...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2024 Company Announcement Net sales of DARZALEX® in the first quarter of 2024 totaled USD 2,692 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; April 16, 2024 – (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by Johnson & Johnson were USD 2,692 million in t...
Transactions in Connection with Share Buy-back Program Genmab
Transactions in Connection with Share Buy-back Program Genmab Company Announcement COPENHAGEN, Denmark; April 15, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. The share buy-back program is expected to be completed no later than December 16, 2024. The following transactions were executed under the program from April 8, 2024 to April 12, 2024: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)Accumulated through last announcement 194,403 400,795,598.95Apr...
- Rune Majlund Dahl
Genmab (Buy, TP: DKK2630.00) - Company consensus added
We have updated our Q1 preview with the company consensus (results due at 17:00 CET on 2 May). We forecast sales c3.5% above consensus, an operating profit margin of 23.2% (consensus 21.6%), and net profit c27.1% above on higher net financials. We expect the 2024 guidance to be maintained, but revised ahead of the Q2 results, due to higher opex related to ProfoundBio. We reiterate our BUY and DKK2,630 target price.
Transactions in Connection with Share Buy-back Program
Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; April 8, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. The share buy-back program is expected to be completed no later than December 16, 2024. The following transactions were executed under the program from April 1, 2024 to April 5, 2024: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)Accumulated through last announcement 121,123 249,025,183.97April 1, 202...
- Rune Majlund Dahl
Genmab (Buy, TP: DKK2630.00) - M&A strategy in play
We view the acquisition of ProfoundBio (for USD1.8bn) as broadly neutral, strengthening the ADC technology platform and expanding the pipeline in gynaecological oncology. With the acquisition, Genmab acquires ProfoundBio’s technology platform and three assets, including the potentially best-in-class drug, Rina-S. We have added Rina-S to our SOTP valuation at DKK118/share (50% LOA), with potential launch in 2027e. We reiterate our BUY and DKK2,630 target price.
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition o...
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio Company Announcement Genmab to acquire ProfoundBio for USD 1.8 billion in cash Acquisition will give Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan (Rina-S), plus ProfoundBio’s novel antibody-drug conjugate (ADC) technology platforms Rina-S is a novel, next-generation, potential best-in-class Topo1 ADC targeting folate receptor alpha (FRα) in development for the treatment of ovarian cancer and other solid tumorsGenmab to host conference call today at 1:00...
Transactions in Connection with Share Buy-back Program
Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; April 2, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. The share buy-back program is expected to be completed no later than December 16, 2024. The following transactions were executed under the program from March 25, 2024 to March 29, 2024: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)Accumulated through last announcement 81,186 165,554,609.26March 2...
Transactions in Connection with Share Buy-back Program
Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; March 25, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares.The share buy-back program is expected to be completed no later than December 16, 2024. The following transactions were executed under the program from March 18, 2024 to March 22, 2024: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK) March 18, 2024XCSE7,7532,051.78 CEUX6,7572,052.57 AQEU7512,054.8...
Completion of share buy-back program
Completion of share buy-back program Company Announcement COPENHAGEN, Denmark; March 18, 2024 – Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on March 15, 2024 On February 14, 2024, Genmab announced the initiation of a share buy-back program to honor our commitments under our Restricted Stock Units program. The share buy-back program was expected to be completed no later than March 15, 2024, and comprised up to 190,000 shares. The following transactions were executed under the program from March 11 to March 15, 2024: No. of sharesAverage price...
Genmab Announces Initiation of Share Buy-Back Program
Genmab Announces Initiation of Share Buy-Back Program Company Announcement Repurchase of up to DKK 3.5 billion worth of sharesCompletion expected no later than December 16, 2024 COPENHAGEN, Denmark; March 15, 2024 – (Nasdaq: GMAB) announced today that it is initiating a share buy-back program. The share buy-back program will be undertaken on the terms set out below and in accordance with Regulation (EU) No. 596/2014 (‘MAR’) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the “Safe Harbour Regulation.” Time frame The share buy-back program will start on Marc...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.